Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

APL2

PreclinicalSmall molecule

Apellis Pharmaceuticals

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

FSGSRecruiting

FSGSPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

FSGS

NCT07213960

Clinical

Trials by Indication[1]

FSGS1 trial

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis

Recruiting· Apellis Pharmaceuticals logo

Apellis Pharmaceuticals·Preclinical·NCT07213960·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APL2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APL2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APL2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apellis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Apellis Pharmaceuticals

Related News